MX9800921A - Quinolonas y su uso terapeutico. - Google Patents
Quinolonas y su uso terapeutico.Info
- Publication number
- MX9800921A MX9800921A MX9800921A MX9800921A MX9800921A MX 9800921 A MX9800921 A MX 9800921A MX 9800921 A MX9800921 A MX 9800921A MX 9800921 A MX9800921 A MX 9800921A MX 9800921 A MX9800921 A MX 9800921A
- Authority
- MX
- Mexico
- Prior art keywords
- quinolones
- therapeutic use
- quinolone
- carboxamides
- phosphodiesterase
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
1-alquil-substituido-quinolona-3-carboxamidas tienen utilidad terapéutica vía inhibicion de la actividad de la Fosfodiesterasa IV esterasa y/o del Factor de necrosis Tumoral.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9515812.7A GB9515812D0 (en) | 1995-08-02 | 1995-08-02 | Novel compounds |
GBGB9523679.0A GB9523679D0 (en) | 1995-11-20 | 1995-11-20 | Novel compounds |
GBGB9605865.6A GB9605865D0 (en) | 1996-03-20 | 1996-03-20 | Novel compounds |
GBGB9611898.9A GB9611898D0 (en) | 1996-06-07 | 1996-06-07 | Quinolones and their therapeutic use |
PCT/GB1996/001866 WO1997004775A1 (en) | 1995-08-02 | 1996-07-31 | Quinolones and their therapeutic use |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9800921A true MX9800921A (es) | 1998-05-31 |
Family
ID=27451320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9800921A MX9800921A (es) | 1995-08-02 | 1996-07-31 | Quinolonas y su uso terapeutico. |
Country Status (10)
Country | Link |
---|---|
US (1) | US5753666A (es) |
EP (1) | EP0841927B1 (es) |
JP (1) | JPH11510156A (es) |
AT (1) | ATE258437T1 (es) |
AU (1) | AU695132B2 (es) |
CA (1) | CA2225555A1 (es) |
DE (1) | DE69631423T2 (es) |
ES (1) | ES2211965T3 (es) |
MX (1) | MX9800921A (es) |
WO (1) | WO1997004775A1 (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9605437D0 (en) * | 1996-03-15 | 1996-05-15 | Iaf Biochem Int | Cytomegalovirus inhibiting compounds |
KR20000068711A (ko) | 1997-08-06 | 2000-11-25 | 도리이 신이치로 | Ⅳ형 포스포디에스테라제 억제제로서의 1-아릴-1,8-나프틸리딘-4-온 유도체 |
WO1999038867A1 (fr) * | 1998-01-29 | 1999-08-05 | Suntory Limited | Derives de 1-cycloalkyle-1,8-naphthyridine-4-one presentant une activite inhibitrice de la phosphodiesterase iv |
AU4849199A (en) * | 1998-07-01 | 2000-01-24 | Celgro | Fungal growth inhibitors |
US6248739B1 (en) * | 1999-01-08 | 2001-06-19 | Pharmacia & Upjohn Company | Quinolinecarboxamides as antiviral agents |
US6624160B2 (en) | 2000-03-21 | 2003-09-23 | Pharmacia & Upjohn Co. | 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents |
JP2003531195A (ja) | 2000-03-21 | 2003-10-21 | ファルマシア・アンド・アップジョン・カンパニー | 抗ウイルス剤としての4−ヒドロキシシンノリン−3−カルボキサミド |
KR20020093849A (ko) | 2000-03-21 | 2002-12-16 | 파마시아 앤드 업존 캄파니 | 항바이러스제로서의4-옥소-1,4-디히드로[1,8]나프티리딘-3-카르복스아미드 |
US6413958B2 (en) | 2000-03-21 | 2002-07-02 | Pharmacia & Upjohn Company | 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
PE20011349A1 (es) * | 2000-06-16 | 2002-01-19 | Upjohn Co | 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales |
US6730682B2 (en) | 2000-07-12 | 2004-05-04 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
US6559145B2 (en) | 2000-07-12 | 2003-05-06 | Pharmacia & Upjohn Company | Heterocycle carboxamides as antiviral agents |
US6562822B2 (en) | 2000-07-12 | 2003-05-13 | Pharmacia & Upjohn Company | Heterocyle carboxamides as antiviral agents |
DE60128936T2 (de) * | 2000-10-12 | 2008-04-10 | Merck & Co, Inc. | Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer |
US6841558B2 (en) * | 2000-10-12 | 2005-01-11 | Merck & Co., Inc. | Aza-and polyaza-naphthalenyl carboxamides useful as HIV intergrase inhibitors |
IL155089A0 (en) * | 2000-10-12 | 2003-10-31 | Merck & Co Inc | Aza and polyaza-naphthalenyl carboxamides useful as hiv integrase inhibitors |
EP1343505A1 (en) | 2000-12-11 | 2003-09-17 | Tularik Inc. | Cxcr3 antagonists |
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
PE20020856A1 (es) * | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
AU2002257459B2 (en) * | 2001-05-24 | 2006-12-14 | Merck Frosst Canada Ltd | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
US6794379B2 (en) | 2001-06-06 | 2004-09-21 | Tularik Inc. | CXCR3 antagonists |
US7323460B2 (en) * | 2002-03-15 | 2008-01-29 | Merck & Co., Inc. | N-(substituted benzyl)-8-hydroxy-1,6-naphthyridine-7-carboxamides useful as HIV integrase inhibitors |
IS7839A (is) * | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
EP1650192A4 (en) * | 2003-07-24 | 2007-03-21 | Astellas Pharma Inc | QUINOLONE DERIVATIVE OR SALT THEREOF |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
ME02970B (me) | 2004-06-24 | 2018-07-20 | Vertex Pharma | Modulatori atp-vezujućih kasetnih transportera |
DE102004035203A1 (de) | 2004-07-21 | 2006-02-16 | Bayer Healthcare Ag | Substituierte Chinolone |
DE102005030524A1 (de) | 2005-06-30 | 2007-01-18 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone II |
TW200800983A (en) * | 2005-09-14 | 2008-01-01 | Janssen Pharmaceutica Nv | 5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase |
CA2629461C (en) * | 2005-11-10 | 2016-01-12 | Anita Melikian | Substituted quinolones and methods of use |
US20090105272A1 (en) * | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
LT1993360T (lt) | 2005-12-28 | 2017-06-12 | Vertex Pharmaceuticals Incorporated | N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma |
DE102006005861A1 (de) | 2006-02-09 | 2007-08-23 | Aicuris Gmbh & Co. Kg | Substituierte Chinolone III |
FR2917413B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl-1,8-naphthyridones, leur preparation et leur application en therapeutique |
FR2917412B1 (fr) | 2007-06-13 | 2009-08-21 | Sanofi Aventis Sa | Derives de 7-alkynyl, 1,8-naphthyridones, leur preparation et leur application en therapeutique |
ES2445442T3 (es) | 2007-09-14 | 2014-03-03 | Vertex Pharmaceuticals Inc. | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
ES2432070T3 (es) | 2009-02-24 | 2013-11-29 | Respiratorius Ab | Diazaheteroarilos broncodilatadores novedosos |
EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
CN102643268B (zh) * | 2011-12-30 | 2014-05-21 | 沈阳药科大学 | 喹啉类及噌啉类化合物及其应用 |
EP2800568A4 (en) * | 2012-01-06 | 2015-06-10 | Univ South Florida | COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR |
WO2013130669A1 (en) | 2012-02-27 | 2013-09-06 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administration thereof |
AU2015330923B2 (en) | 2014-10-07 | 2020-03-12 | Vertex Pharmaceuticals Incorporated | Co-crystals of modulators of cystic fibrosis transmembrane conductance regulator |
CN107998131B (zh) * | 2017-12-27 | 2019-09-24 | 湖北工业大学 | 芳香酯类化合物用于制备抗adv-7病毒药物 |
CN111646941A (zh) * | 2020-07-17 | 2020-09-11 | 天津科技大学 | 一种磺酰胺类衍生物及其制备方法和应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3524858A (en) * | 1967-05-18 | 1970-08-18 | Warner Lambert Pharmaceutical | 1,4 - dihydro-1-substituted alkyl-6,7-methylenedioxy - 4 - oxoquinoline-3-carboxylic acid |
FR2564832B1 (fr) * | 1984-05-23 | 1987-05-15 | Panmedica Sa | Nouveaux n-acyl derives d'amino-acides et leurs esters, leur procede de preparation et medicaments les contenant |
US4786644A (en) * | 1987-11-27 | 1988-11-22 | Hoechst-Roussel Pharmaceuticals Inc. | 1-aryl-3-quinolinecarboxamide |
JPH02124871A (ja) * | 1988-07-27 | 1990-05-14 | Dainippon Pharmaceut Co Ltd | 1位が置換された複素環式カルボン酸アミド誘導体 |
-
1996
- 1996-07-31 AU AU66266/96A patent/AU695132B2/en not_active Ceased
- 1996-07-31 WO PCT/GB1996/001866 patent/WO1997004775A1/en active IP Right Grant
- 1996-07-31 DE DE69631423T patent/DE69631423T2/de not_active Expired - Fee Related
- 1996-07-31 MX MX9800921A patent/MX9800921A/es not_active IP Right Cessation
- 1996-07-31 JP JP9507375A patent/JPH11510156A/ja not_active Ceased
- 1996-07-31 EP EP96925909A patent/EP0841927B1/en not_active Expired - Lifetime
- 1996-07-31 CA CA002225555A patent/CA2225555A1/en not_active Abandoned
- 1996-07-31 AT AT96925909T patent/ATE258437T1/de not_active IP Right Cessation
- 1996-07-31 ES ES96925909T patent/ES2211965T3/es not_active Expired - Lifetime
- 1996-08-02 US US08/691,339 patent/US5753666A/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2225555A1 (en) | 1997-02-13 |
ES2211965T3 (es) | 2004-07-16 |
EP0841927A1 (en) | 1998-05-20 |
AU6626696A (en) | 1997-02-26 |
DE69631423D1 (de) | 2004-03-04 |
DE69631423T2 (de) | 2004-12-02 |
JPH11510156A (ja) | 1999-09-07 |
WO1997004775A1 (en) | 1997-02-13 |
US5753666A (en) | 1998-05-19 |
AU695132B2 (en) | 1998-08-06 |
EP0841927B1 (en) | 2004-01-28 |
ATE258437T1 (de) | 2004-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9800921A (es) | Quinolonas y su uso terapeutico. | |
MX9800922A (es) | Quinolonas y su uso terapeutico. | |
AU4960297A (en) | Bicyclic aryl carboxamides and their therapeutic use | |
IL136738A0 (en) | Inhibition of p38 kinase activity using substituted heterocyclic ureas | |
HK1031832A1 (en) | Inhibition of p38 kinase activity using aryl and heteroaryl substituted heterocyclic ureas | |
AU7585498A (en) | Inhibition of p38 kinase activity by aryl ureas | |
AU3738393A (en) | Compounds useful for treating inflammatory diseases and for inhibiting production of tumor necrosis factor | |
DK0696205T3 (da) | Anvendelse af neuro-afledte fetale cellelinier til transplantationsterapi | |
AU6276194A (en) | Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer | |
AU6097094A (en) | Antisense polynucleotide inhibition of human growth factor-sensitive cancer cells | |
AU5093593A (en) | Inhibition of tumor metastasis via neutralization of tissue factor function | |
AU5788396A (en) | Methods of inhibition or killing of cancer cells | |
UA66793C2 (uk) | Лептин як стримувач швидкого збільшення пухлини клітини | |
AU3000297A (en) | Use of protein kinase c inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy | |
AU5354394A (en) | Beta -agonist, alpha1-agonist, and/or alpha2-antagonist treatment of neurodegenerative diseases and central nervous system trauma | |
AU5962396A (en) | Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and deri vatives thereof | |
AU3400297A (en) | Gm-csf administration for the treatment and prevention of recurrence of brain tumors | |
AU7278294A (en) | Use of quinoline-3-carboxamide compounds for inhibiting the production of tumour necrosis factor (tnf) and/or for the treatment of septic shock | |
AU4808593A (en) | Use of pentoxifylline and other tumor necrosis factor blockers for the treatment of aids-associated optic neuropathy and other central nervous system diseases | |
AU8742198A (en) | Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity | |
EP0656069A4 (en) | CELL PROLIFERATION INHIBITORS, THEIR PRODUCTION AND USE. | |
EP0716614A4 (en) | TREATMENT OF HUMAN TUMORS BY GENETIC TRANSFORMATION OF HUMAN TUMORS | |
AU2265695A (en) | The use of sertraline to treat cancer patients | |
AU6777596A (en) | Treatment of human prostate disease with beta-lapachone derivatives | |
EP0733365A3 (en) | Use of benzoquinolin-3-one for the treatment and prevention of prostate cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |